This is an 18-week open-label, multicenter study to evaluate the efficacy and tolerability of CEP-701 (lestaurtinib) treatment in patients with Polycythemia Vera (PV) and patients with Essential Thrombocytosis (ET).
Name: lestaurtinib
Allocation: N/A
Single Group Assignment
There is one SNP
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation. --- V617F ---
Determine whether a specific reduction in the JAK2 V617F allele has been indicated in this study.. null. --- V617F ---
- The patient has a detectable JAK2 V617F mutation. --- V617F ---